{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:44:32Z","timestamp":1773305072349,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["111-2118-M-002 -004 -MY2"],"award-info":[{"award-number":["111-2118-M-002 -004 -MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 110-2811-M-002 -633"],"award-info":[{"award-number":["MOST 110-2811-M-002 -633"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Evaluating the magnitude of overdiagnosis associated with stool-based service screening for colorectal cancer (CRC) beyond a randomized controlled trial is often intractable and understudied. We aim to estimate the proportion of overdiagnosis in population-based service screening programs for CRC with the fecal immunochemical test (FIT). The natural process of overdiagnosis-embedded disease was first built up to learn transition parameters that quantify the pathway of non-progressive and progressive screen-detected cases calibrated with sensitivity, while also taking competing mortality into account. The Markov algorithms were then developed for estimating these transition parameters based on Taiwan FIT service CRC screening data on 5,417,699 residents aged 50\u201369 years from 2004 to 2014. Following the digital twin design with the parallel universe structure for emulating the randomized controlled trial, the screened twin, mirroring the control group without screening, was virtually recreated by the application of the above-mentioned trained parameters to predict CRC cases containing overdiagnosis. The ratio of the predicted CRCs derived from the screened twin to the observed CRCs of the control group minus 1 was imputed to measure the extent of overdiagnosis. The extent of overdiagnosis for invasive CRCs resulting from FIT screening is 4.16% (95% CI: 2.61\u20135.78%). The corresponding figure is increased to 9.90% (95% CI: 8.41\u201311.42%) for including high grade dysplasia (HGD) and further inflated to 15.83% (95% CI: 15.23\u201316.46%) when the removal adenoma is considered. The modest proportion of overdiagnosis modelled by the digital twin method, dispensing with the randomized controlled trial design, suggests the harm done to population-based FIT service screening is negligible.<\/jats:p>","DOI":"10.1038\/s41746-023-00763-5","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T06:03:04Z","timestamp":1676008984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Assessing overdiagnosis of fecal immunological test screening for colorectal cancer with a digital twin approach"],"prefix":"10.1038","volume":"6","author":[{"given":"Ting-Yu","family":"Lin","sequence":"first","affiliation":[]},{"given":"Sherry Yueh-Hsia","family":"Chiu","sequence":"additional","affiliation":[]},{"given":"Ling-Chun","family":"Liao","sequence":"additional","affiliation":[]},{"given":"Sam Li-Sheng","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Han-Mo","family":"Chiu","sequence":"additional","affiliation":[]},{"given":"Tony Hsiu-Hsi","family":"Chen","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"763_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(96)03430-7","volume":"348","author":"O Kronborg","year":"1996","unstructured":"Kronborg, O., Fenger, C., Olsen, J., J\u00f8rgensen, O. D. & S\u00f8ndergaard, O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348, 1467\u20131471 (1996).","journal-title":"Lancet"},{"key":"763_CR2","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S0140-6736(96)03386-7","volume":"348","author":"JD Hardcastle","year":"1996","unstructured":"Hardcastle, J. D. et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348, 1472\u20131477 (1996).","journal-title":"Lancet"},{"key":"763_CR3","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1056\/NEJM199305133281901","volume":"328","author":"JS Mandel","year":"1993","unstructured":"Mandel, J. S. et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N. Engl. J. Med. 328, 1365\u20131371 (1993).","journal-title":"N. Engl. J. Med."},{"key":"763_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/bjs.6136","volume":"95","author":"E Lindholm","year":"2008","unstructured":"Lindholm, E., Brevinge, H. & Haglind, E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. J. Br. Surg. 95, 1029\u20131036 (2008).","journal-title":"J. Br. Surg."},{"key":"763_CR5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/gutjnl-2014-307508","volume":"64","author":"M Zorzi","year":"2015","unstructured":"Zorzi, M. et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut 64, 784\u2013790 (2015).","journal-title":"Gut"},{"key":"763_CR6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2018.07.017","volume":"155","author":"TR Levin","year":"2018","unstructured":"Levin, T. R. et al. Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population. Gastroenterology 155, 1383\u20131391 (2018).","journal-title":"Gastroenterology"},{"key":"763_CR7","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1136\/gutjnl-2020-322545","volume":"70","author":"HM Chiu","year":"2021","unstructured":"Chiu, H. M. et al. Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers. Gut 70, 2321\u20132329 (2021).","journal-title":"Gut"},{"key":"763_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1053\/j.gastro.2018.07.037","volume":"155","author":"M Kalager","year":"2018","unstructured":"Kalager, M. et al. Overdiagnosis in colorectal cancer screening: time to acknowledge a blind spot. Gastroenterology 155, 592\u2013595 (2018).","journal-title":"Gastroenterology"},{"key":"763_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.bjc.6603246","volume":"95","author":"N Pashayan","year":"2006","unstructured":"Pashayan, N., Powles, J., Brown, C. & Duffy, S. W. Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia. Br. J. cancer 95, 401\u2013405 (2006).","journal-title":"Br. J. cancer"},{"key":"763_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1541-0420.2007.00825.x","volume":"64","author":"D Telesca","year":"2008","unstructured":"Telesca, D., Etzioni, R. & Gulati, R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 64, 10\u201319 (2008).","journal-title":"Biometrics"},{"key":"763_CR11","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"US Preventive Services Task Force.","year":"2018","unstructured":"US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Jama 319, 1901\u20131913 (2018).","journal-title":"Jama"},{"key":"763_CR12","doi-asserted-by":"publisher","first-page":"e042158","DOI":"10.1136\/bmjopen-2020-042158","volume":"11","author":"P Wieszczy","year":"2021","unstructured":"Wieszczy, P. et al. Estimation of overdiagnosis in colorectal cancer screening with sigmoidoscopy and faecal occult blood testing: comparison of simulation models. BMJ open 11, e042158 (2021).","journal-title":"BMJ open"},{"key":"763_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/0969141319842910","volume":"26","author":"M Hakama","year":"2019","unstructured":"Hakama, M. & Malila, N. Estimation of overdiagnosis by detection to incidence ratio in cancer screening. J. Med. Screen. 26, 135\u2013138 (2019).","journal-title":"J. Med. Screen."},{"key":"763_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/biostatistics\/kxh012","volume":"5","author":"O Davidov","year":"2004","unstructured":"Davidov, O. & Zelen, M. Overdiagnosis in early detection programs. Biostatistics 5, 603\u2013613 (2004).","journal-title":"Biostatistics"},{"key":"763_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/bimj.201000107","volume":"54","author":"GHM Wu","year":"2012","unstructured":"Wu, G. H. M. et al. A stochastic model for survival of early prostate cancer with adjustments for leadtime, length bias, and over\u2010detection. Biom. J. 54, 20\u201344 (2012).","journal-title":"Biom. J."},{"key":"763_CR16","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1126\/science.abh1645","volume":"373","author":"T Ushijima","year":"2021","unstructured":"Ushijima, T., Clark, S. J. & Tan, P. Mapping genomic and epigenomic evolution in cancer ecosystems. Science 373, 1474\u20131479 (2021).","journal-title":"Science"},{"key":"763_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2310\/7750.2010.09015","volume":"14","author":"JK Rivers","year":"2010","unstructured":"Rivers, J. K. & Wulkan, S. The case for early detection of melanoma. J. Cutan. Med. Surg. 14, 24\u201329 (2010).","journal-title":"J. Cutan. Med. Surg."},{"key":"763_CR18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/sci2020031","volume":"2","author":"SM Schwartz","year":"2020","unstructured":"Schwartz, S. M., Wildenhaus, K., Bucher, A. & Byrd, B. Digital twins and the emerging science of self: Implications for digital health experience design and \u201csmall\u201d data. Frontiers in Computer. Science 2, 31 (2020).","journal-title":"Science"},{"key":"763_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1126\/science.aaw7086","volume":"364","author":"M L\u00f6brich","year":"2019","unstructured":"L\u00f6brich, M. & Jeggo, P. A. Hazards of human spaceflight. Science 364, 127\u2013128 (2019).","journal-title":"Science"},{"key":"763_CR20","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1126\/science.abf3370","volume":"371","author":"R Laubenbacher","year":"2021","unstructured":"Laubenbacher, R., Sluka, J. P. & Glazier, J. A. Using digital twins in viral infection. Science 371, 1105\u20131106 (2021).","journal-title":"Science"},{"key":"763_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.tem.2019.04.008","volume":"30","author":"B Kovatchev","year":"2019","unstructured":"Kovatchev, B. A century of diabetes technology: signals, models, and artificial pancreas control. Trends Endocrinol. Metab. 30, 432\u2013444 (2019).","journal-title":"Trends Endocrinol. Metab."},{"key":"763_CR22","doi-asserted-by":"publisher","first-page":"djv103","DOI":"10.1093\/jnci\/djv103","volume":"107","author":"NT Van Ravesteyn","year":"2015","unstructured":"Van Ravesteyn, N. T. et al. Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis. J. Natl Cancer Inst. 107, djv103 (2015).","journal-title":"J. Natl Cancer Inst."},{"key":"763_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7326\/M13-2867","volume":"161","author":"I Lansdorp-Vogelaar","year":"2014","unstructured":"Lansdorp-Vogelaar, I. et al. Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann. Intern. Med. 161, 104\u2013112 (2014).","journal-title":"Ann. Intern. Med."},{"key":"763_CR24","doi-asserted-by":"publisher","first-page":"54S","DOI":"10.1177\/0272989X17711928","volume":"38","author":"JJ van den Broek","year":"2018","unstructured":"van den Broek, J. J., van Ravesteyn, N. T., Heijnsdijk, E. A. & de Koning, H. J. Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia. Med. Decis. Mak.: Int. J. Soc. Med. Decis. Mak. 38, 54S\u201365S (2018).","journal-title":"Med. Decis. Mak.: Int. J. Soc. Med. Decis. Mak."},{"key":"763_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/CEG.S86419","volume":"8","author":"SH Elsafi","year":"2015","unstructured":"Elsafi, S. H., Alqahtani, N. I., Zakary, N. Y. & Al Zahrani, E. M. The sensitivity, specificity, predictive values, and likelihood ratios of fecal occult blood test for the detection of colorectal cancer in hospital settings. Clin. Exp. Gastroenterol. 8, 279 (2015).","journal-title":"Clin. Exp. Gastroenterol."},{"key":"763_CR26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/jnci\/djp001","volume":"101","author":"G Draisma","year":"2009","unstructured":"Draisma, G. et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J. Natl Cancer Inst. 101, 374\u2013383 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"763_CR27","doi-asserted-by":"publisher","first-page":"e022457","DOI":"10.1136\/bmjopen-2018-022457","volume":"9","author":"T Pathirana","year":"2019","unstructured":"Pathirana, T., Hayen, A., Doust, J., Glasziou, P. & Bell, K. Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach. BMJ open 9, e022457 (2019).","journal-title":"BMJ open"},{"key":"763_CR28","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/sim.8437","volume":"39","author":"AMF Yen","year":"2020","unstructured":"Yen, A. M. F. & Chen, H. H. Modeling the overdetection of screen\u2010identified cancers in population\u2010based cancer screening with the Coxian phase\u2010type Markov process. Stat. Med. 39, 660\u2013673 (2020).","journal-title":"Stat. Med."},{"key":"763_CR29","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1002\/cncr.29952","volume":"122","author":"MP van der Meulen","year":"2016","unstructured":"van der Meulen, M. P., Lansdorp-Vogelaar, I., van Heijningen, E. M., Kuipers, E. J. & van Ballegooijen, M. Nonbleeding adenomas: Evidence of systematic false-negative fecal immunochemical test results and their implications for screening effectiveness-A modeling study. Cancer 122, 1680\u20131688 (2016).","journal-title":"Cancer"},{"key":"763_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/02813432.2019.1608040","volume":"37","author":"EL Toft","year":"2019","unstructured":"Toft, E. L., Kaae, S. E., Malmqvist, J. & Brodersen, J. Psychosocial consequences of receiving false-positive colorectal cancer screening results: a qualitative study. Scand. J. Prim. Health Care 37, 145\u2013154 (2019).","journal-title":"Scand. J. Prim. Health Care"},{"key":"763_CR31","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1053\/j.gastro.2011.02.054","volume":"140","author":"DM Booth","year":"2011","unstructured":"Booth, D. M. et al. Reactive oxygen species induced by bile acid induce apoptosis and protect against necrosis in pancreatic acinar cells. Gastroenterology 140, 2116\u20132125 (2011).","journal-title":"Gastroenterology"},{"key":"763_CR32","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1116::AID-CNCR4>3.0.CO;2-D","volume":"86","author":"THH Chen","year":"1999","unstructured":"Chen, T. H. H. et al. Evaluation of a selective screening for colorectal carcinoma: the Taiwan Multicenter Cancer Screening (TAMCAS) project. Cancer.: Interdiscip. Int. J. Am. Cancer. Soc. 86, 1116\u20131128 (1999).","journal-title":"Cancer.: Interdiscip. Int. J. Am. Cancer. Soc."},{"key":"763_CR33","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/1055-9965.EPI-09-1028","volume":"19","author":"SYH Chiu","year":"2010","unstructured":"Chiu, S. Y. H. et al. Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening. Cancer Epidemiol. Prev. Biomark. 19, 1219\u20131228 (2010).","journal-title":"Cancer Epidemiol. Prev. Biomark."},{"key":"763_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.0006-341X.2000.00167.x","volume":"56","author":"TH Chen","year":"2000","unstructured":"Chen, T. H. et al. Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics 56, 167\u2013172 (2000).","journal-title":"Biometrics"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00763-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00763-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00763-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T16:15:48Z","timestamp":1676304948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00763-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1038\/s41746-023-00763-5","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"27 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}